Marit A C Vermunt1, Lisa T van der Heijden2, Jeroen J M A Hendrikx2,3, Alfred H Schinkel2, Vincent A de Weger2, Eric van der Putten4, Baukelien van Triest5, Andries M Bergman6, Jos H Beijnen2,4,7. 1. Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Plesmanlaan 121, Amsterdam, 1066CX, The Netherlands. m.vermunt@nki.nl. 2. Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Plesmanlaan 121, Amsterdam, 1066CX, The Netherlands. 3. Department of Nuclear Medicine, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Plesmanlaan 121, Amsterdam, 1066CX, The Netherlands. 4. Modra Pharmaceuticals BV, Barbara Strozzilaan 201, Amsterdam, 1083HN, The Netherlands. 5. Department of Radiotherapy, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Plesmanlaan 121, Amsterdam, 1066CX, The Netherlands. 6. Department of Medical Oncology and Oncogenomics, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Plesmanlaan 121, Amsterdam, 1066CX, The Netherlands. 7. Department of Pharmaceutical Sciences, Utrecht University, Heidelberglaan 100, Utrecht, 3584CX, The Netherlands.
Abstract
PURPOSE: ModraDoc006 is a novel oral formulation of docetaxel. The clearance of intravenous docetaxel is higher in medically castrated prostate cancer patients as compared to patients with other types of solid tumours. Oral docetaxel requires co-administration ritonavir (r), which might further impact the pharmacokinetics (PK). We now compare the PK of docetaxel and ritonavir between patients with Hormone Sensitive Prostate Cancer (HSPC), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other metastatic solid tumours, treated on the same dose and weekly schedule of ModraDoc006/r. METHODS: The docetaxel and ritonavir PK were compared between four patient groups from three clinical phase I trials, including eight male and eight female patients with different types of solid tumours (study 1), seven patients with HSPC (study 2) and five patients with mCRPC (study 3). All patients were treated with ModraDoc006 30 mg and ritonavir 100 mg in the morning, followed by ModraDoc006 20 mg and ritonavir 100 mg in the evening (ModraDoc006/r 30-20/100-100). For comparative purposes, the PK of six mCRPC patients that received 30-20/200-100 in study 3 were also evaluated. RESULTS: The maximum plasma concentration (Cmax) was significantly lower for both docetaxel and ritonavir in the prostate cancer patients as compared to the patients with other types of solid tumours treated at ModraDoc006/r 30-20/100-100. The docetaxel area under the plasma concentration versus time curve (AUC) was significantly different at this dose, with a mean AUC0-48 of 1359 ± 374 ng/mL*h (N = 8) in female patients and 894 ± 223 ng/mL*h (N = 8) in male patients with different solid tumours (study 1), 321 ± 81 (N = 7) in HSPC (study 2) and 367 ± 182 ng/mL*h (N = 5) in mCRPC (study 3). A similar pattern was observed for ritonavir. ModraDoc006/r 30-20/200-100 in six mCRPC patients led to a comparable ritonavir exposure as compared to the patients at 30-20/100-100 in study 1 and increased the docetaxel AUC0-48 to 1266 ± 473 ng/mL*h (N = 6). CONCLUSION: The exposure to docetaxel and ritonavir was significantly lower in prostate cancer patients as compared to patients with other types of solid tumours, treated on ModraDoc006/r 30-20/100-100. An increase of the ritonavir dose increased the docetaxel exposure in mCRPC patients. Therefore, a different RP2D of ModraDoc006/r is pursued in castrated prostate cancer patients as compared to patients with other types of solid tumours. TRIAL REGISTRATION: Study 1: ClinicalTrials.gov Identifier NCT01173913, date of registration August 2, 2010. Study 2: ClinicalTrials.gov Identifier NCT03066154, date of registration February 28, 2017. Study 3: ClinicalTrials.gov Identifier NCT03136640, date of registration May 2, 2017.
PURPOSE:ModraDoc006 is a novel oral formulation of docetaxel. The clearance of intravenous docetaxel is higher in medically castrated prostate cancerpatients as compared to patients with other types of solid tumours. Oral docetaxel requires co-administration ritonavir (r), which might further impact the pharmacokinetics (PK). We now compare the PK of docetaxel and ritonavir between patients with Hormone Sensitive Prostate Cancer (HSPC), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other metastatic solid tumours, treated on the same dose and weekly schedule of ModraDoc006/r. METHODS: The docetaxel and ritonavir PK were compared between four patient groups from three clinical phase I trials, including eight male and eight female patients with different types of solid tumours (study 1), seven patients with HSPC (study 2) and five patients with mCRPC (study 3). All patients were treated with ModraDoc006 30 mg and ritonavir 100 mg in the morning, followed by ModraDoc006 20 mg and ritonavir 100 mg in the evening (ModraDoc006/r 30-20/100-100). For comparative purposes, the PK of six mCRPC patients that received 30-20/200-100 in study 3 were also evaluated. RESULTS: The maximum plasma concentration (Cmax) was significantly lower for both docetaxel and ritonavir in the prostate cancerpatients as compared to the patients with other types of solid tumours treated at ModraDoc006/r 30-20/100-100. The docetaxel area under the plasma concentration versus time curve (AUC) was significantly different at this dose, with a mean AUC0-48 of 1359 ± 374 ng/mL*h (N = 8) in female patients and 894 ± 223 ng/mL*h (N = 8) in male patients with different solid tumours (study 1), 321 ± 81 (N = 7) in HSPC (study 2) and 367 ± 182 ng/mL*h (N = 5) in mCRPC (study 3). A similar pattern was observed for ritonavir. ModraDoc006/r 30-20/200-100 in six mCRPC patients led to a comparable ritonavir exposure as compared to the patients at 30-20/100-100 in study 1 and increased the docetaxel AUC0-48 to 1266 ± 473 ng/mL*h (N = 6). CONCLUSION: The exposure to docetaxel and ritonavir was significantly lower in prostate cancerpatients as compared to patients with other types of solid tumours, treated on ModraDoc006/r 30-20/100-100. An increase of the ritonavir dose increased the docetaxel exposure in mCRPC patients. Therefore, a different RP2D of ModraDoc006/r is pursued in castrated prostate cancerpatients as compared to patients with other types of solid tumours. TRIAL REGISTRATION: Study 1: ClinicalTrials.gov Identifier NCT01173913, date of registration August 2, 2010. Study 2: ClinicalTrials.gov Identifier NCT03066154, date of registration February 28, 2017. Study 3: ClinicalTrials.gov Identifier NCT03136640, date of registration May 2, 2017.
Authors: Heleen A Bardelmeijer; Mariët Ouwehand; Tessa Buckle; Maarten T Huisman; Jan H M Schellens; Jos H Beijnen; Olaf van Tellingen Journal: Cancer Res Date: 2002-11-01 Impact factor: 12.701
Authors: Vincent A de Weger; Frederik E Stuurman; Jeroen J M A Hendrikx; Johannes J Moes; Emilia Sawicki; Alwin D R Huitema; Bastiaan Nuijen; Bas Thijssen; Hilde Rosing; Marianne Keessen; Marja Mergui-Roelvink; Jos H Beijnen; Jan H M Schellens; Serena Marchetti Journal: Eur J Cancer Date: 2017-10-12 Impact factor: 9.162
Authors: Vincent A de Weger; Frederik E Stuurman; Stijn L W Koolen; Johannes J Moes; Jeroen J M A Hendrikx; Emilia Sawicki; Bas Thijssen; Marianne Keessen; Hilde Rosing; Marja Mergui-Roelvink; Alwin D R Huitema; Bastiaan Nuijen; Jos H Beijnen; Jan H M Schellens; Serena Marchetti Journal: Clin Cancer Res Date: 2019-06-19 Impact factor: 12.531
Authors: Robert A B van Waterschoot; Jurjen S Lagas; Els Wagenaar; Cornelia M M van der Kruijssen; Antonius E van Herwaarden; Ji-Ying Song; Rogier W Rooswinkel; Olaf van Tellingen; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel Journal: Cancer Res Date: 2009-11-17 Impact factor: 12.701
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Roos L Oostendorp; Alwin Huitema; Hilde Rosing; Robert S Jansen; Rob Ter Heine; Marianne Keessen; Jos H Beijnen; Jan H M Schellens Journal: Clin Cancer Res Date: 2009-06-09 Impact factor: 12.531
Authors: Leora Horn; David R Spigel; Everett E Vokes; Esther Holgado; Neal Ready; Martin Steins; Elena Poddubskaya; Hossein Borghaei; Enriqueta Felip; Luis Paz-Ares; Adam Pluzanski; Karen L Reckamp; Marco A Burgio; Martin Kohlhäeufl; David Waterhouse; Fabrice Barlesi; Scott Antonia; Oscar Arrieta; Jérôme Fayette; Lucio Crinò; Naiyer Rizvi; Martin Reck; Matthew D Hellmann; William J Geese; Ang Li; Anne Blackwood-Chirchir; Diane Healey; Julie Brahmer; Wilfried E E Eberhardt Journal: J Clin Oncol Date: 2017-10-12 Impact factor: 44.544
Authors: Claire L Vale; Sarah Burdett; Larysa H M Rydzewska; Laurence Albiges; Noel W Clarke; David Fisher; Karim Fizazi; Gwenaelle Gravis; Nicholas D James; Malcolm D Mason; Mahesh K B Parmar; Christopher J Sweeney; Matthew R Sydes; Bertrand Tombal; Jayne F Tierney Journal: Lancet Oncol Date: 2015-12-21 Impact factor: 41.316
Authors: Aurelia H M de Vries Schultink; Marie-Rose B S Crombag; Erik van Werkhoven; Hans-Martin Otten; Andre M Bergman; Jan H M Schellens; Alwin D R Huitema; Jos H Beijnen Journal: Cancer Med Date: 2019-02-22 Impact factor: 4.452
Authors: Giacomo Miserocchi; Chiara Spadazzi; Sebastiano Calpona; Francesco De Rosa; Alice Usai; Alessandro De Vita; Chiara Liverani; Claudia Cocchi; Silvia Vanni; Chiara Calabrese; Massimo Bassi; Giovanni De Luca; Giuseppe Meccariello; Toni Ibrahim; Marco Schiavone; Laura Mercatali Journal: J Pers Med Date: 2022-05-24
Authors: Marit A C Vermunt; Merel van Nuland; Lisa T van der Heijden; Hilde Rosing; Jos H Beijnen; Andries M Bergman Journal: Cancer Chemother Pharmacol Date: 2022-04-25 Impact factor: 3.288